StreetInsider.com News Articles

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today announced it will host its first live virtual R&D Webcast on Thursday, June 18, 2026, at 10:00 a.m. Eastern Time.

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Mon, 08 Jun 2026 08:04:00 -0400

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis

Form 8-K Transcode Therapeutics, For: Jun 03

Wed, 03 Jun 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260603/26595788.html

Form 8-K Transcode Therapeutics, For: Jun 03

Wed, 03 Jun 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260603/26595788.html

TransCode completes phase 1a cancer trial with no dose-limiting toxicities

Wed, 03 Jun 2026 08:04:21 -0400

TransCode Therapeutics Inc. (NASDAQ: RNAZ) completed its Phase 1a clinical trial for TTX-MC138, an experimental cancer treatment, meeting the primary safety endpoint with no dose-limiting toxicities observed across all tested doses.

The trial enrolled 16 patients with metastatic cancer who received 86 doses of TTX-MC138, designed to inhibit microRNA-10b. The median treatment duration was 11.3 weeks, ranging from four to 52.4 weeks. Three patients remain on the trial, with one receiving 21 treatment cycles.

According to Response Evaluation Criteria in Solid Tumors standards, nine out of 14 evaluable patients achieved stable disease lasting six months. The company tested four dose levels ranging

TransCode completes phase 1a cancer trial with no dose-limiting toxicities

Wed, 03 Jun 2026 08:04:21 -0400

According to Response Evaluation Criteria in Solid Tumors standards, nine out of 14 evaluable patients achieved stable disease lasting six months. The company tested four dose levels ranging

TransCode completes phase 1a cancer trial with no dose-limiting toxicities

Wed, 03 Jun 2026 08:04:21 -0400

According to Response Evaluation Criteria in Solid Tumors standards, nine out of 14 evaluable patients achieved stable disease lasting six months. The company tested four dose levels ranging

TransCode completes phase 1a cancer trial with no dose-limiting toxicities

Wed, 03 Jun 2026 08:04:21 -0400

According to Response Evaluation Criteria in Solid Tumors standards, nine out of 14 evaluable patients achieved stable disease lasting six months. The company tested four dose levels ranging

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer